BIOGEN INC
For the period ended Dec 31, 2023. Filed Feb 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 14, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
a. (1) Consolidated Financial Statements:
The following financial statements are filed as part of this report:
| Financial Statements | Page Number | |
|---|---|---|
| Consolidated Statements of Income | F-2 | |
| Consolidated Statements of Comprehensive Income | F-3 | |
| Consolidated Balance Sheets | F-4 | |
| Consolidated Statements of Cash Flow | F-5 | |
| Consolidated Statements of Equity | F-6 | |
| Notes to Consolidated Financial Statements | F-9 | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID 238) | F-83 |
Certain totals may not sum due to rounding.
(2) Exhibits
The exhibits listed on the Exhibit Index beginning on page 98, which is incorporated herein by reference, are filed or furnished as part of this report or are incorporated into this report by reference.
(3) Financial Statement Schedules
Schedules are omitted because they are not applicable, or are not required, or because the information is included in the consolidated financial statements and notes thereto.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.